Related Experiment Video
Updated: Aug 16, 2026
06:52
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Central serotonergic hyperresponsivity in late-onset Alzheimer's disease
D M McLoughlin1, J V Lucey, T G Dinan
1Department of Psychiatry, Trinity College Medical School, St. James's Hospital, London, England.
The American Journal of Psychiatry
|November 1, 1994
Summary
Patients with late-onset Alzheimer's disease showed a heightened prolactin response to d-fenfluramine, indicating increased central serotonin responsivity. This suggests a potential difference in serotonin system function in Alzheimer's disease.
Area of Science:
- Neuroscience
- Gerontology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder impacting cognitive function.
- Serotonin system alterations are implicated in the pathophysiology of AD.
- Understanding central neurotransmitter responsivity is crucial for AD research.
Purpose of the Study:
- To investigate central serotonin system responsivity in patients with late-onset Alzheimer's disease.
- To compare serotonin-mediated prolactin release between AD patients and a healthy elderly comparison group.
Main Methods:
- A controlled study involving nine patients with late-onset Alzheimer's disease and an elderly comparison group.
- Administration of oral d-fenfluramine (30 mg) to assess the prolactin response.
- Measurement of prolactin levels to quantify serotonin pathway activity.
Main Results:
- Patients with Alzheimer's disease exhibited a significantly greater prolactin response compared to the elderly comparison group.
- The observed prolactin increase is mediated by the serotonin system.
- This suggests an augmented central serotonin responsivity in individuals with Alzheimer's disease.
Conclusions:
- Central serotonin responsivity appears to be greater in patients with late-onset Alzheimer's disease.
- These findings may offer insights into the neurobiological mechanisms underlying Alzheimer's disease.
- Further research is warranted to explore the implications of altered serotonin function in AD.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...